Fatal hydrocodone overdose in a child: Pharmacogenetics and drug interactions

Pediatrics

Volumn 126, Issue 4, 2010, Pages

  Madadi, Parvaz ^a   Hildebrandt, Doris ^b   Gong, Inna Y ^c   Schwarz, Ute I ^c   Ciszkowski, Catherine ^c   Ross, Colin J D ^d,e   Sistonen, Johanna ^d,e   Carleton, Bruce C ^d,e   Hayden, Michael R ^d,e   Lauwers, Albert E ^b   Koren, Gideon ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Ministry of Community Safety and Correctional Services   (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Adverse drug event; Child; Clarithromycin; CYP2D6; CYP3A4; Hydrocodone; Valproic acid

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 2D6; HYDROCODONE; VALPROIC ACID; ANTITUSSIVE AGENT;

ARTICLE; AUTOPSY; CASE REPORT; CHILD; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FATALITY; DRUG METABOLISM; DRUG OVERDOSE; EAR INFECTION; ENZYME ACTIVITY; FEMALE; GAS CHROMATOGRAPHY; GENE DELETION; GENE DUPLICATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; MASS SPECTROMETRY; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RHINORRHEA; SEIZURE; DRUG INTERACTION; FATALITY; METABOLISM;

ANTITUSSIVE AGENTS; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FATAL OUTCOME; FEMALE; HUMANS; HYDROCODONE; OVERDOSE; VALPROIC ACID; DRUG OVERDOSE;

EID: 77957694829     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-1907     Document Type: Article

References (27)

1. Simasek M, Blandino DA. Treatment of the common cold. Am Fam Physician. 2007;75(4):515-520
2. Stolz D, Chhajed PN, Leuppi JD, Brutsche M, Pflimlin E, Tamm M. Cough suppression during flexible bronchoscopy using combined sedation with midazolam and hydrocodone: a randomised, double blind, placebo controlled trial. Thorax. 2004;59(9):773-776
3. US Food and Drug Administration. FDA takes action to stop marketing of unapproved hydrocodone products: action to impact approximately 200 cough-suppressant products [press release]. Available at: www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2007/ ucm108997.htm. Accessed July 16, 2009
4. Mitka M. FDA bans sale of unapproved cough suppressants containing hydrocodone. JAMA. 2007;298(19):2251-2252 (Pubitemid 350146234)
5. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci. 1991;48(22):2165-2171
6. Cone EJ, Darwin WD, Gorodetzky CW, Tan T. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos. 1978;6(4):488-493
7. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993;54(5):463-472
8. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004;57(3):287-297 (Pubitemid 38296992)
9. Cone EJ, Darwin WD. Simultaneous determination of hydromorphone, hydrocodone and their 6alpha- and 6beta-hydroxy metabolites in urine using selected ion recording with methane chemical ionization. Biomed Mass Spectrom. 1978;5(4):291
10. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17(2):93-101 (Pubitemid 46263424)
11. Watterson J, Peaire A, Hinman J. Elevated morphine concentrations determined during infant death investigations: artifacts of withdrawal of care. J Forensic Sci. 2008;53(4):1001-1004
12. Lalonde BR, Wallage HR. Postmortem blood ketamine distribution in two fatalities. J Anal Toxicol. 2004;28(1):71-74
13. Spiller HA. Postmortem oxycodone and hydrocodone blood concentrations. J Forensic Sci. 2003;48(2):429-431
14. Ueshima S, Aiba T, Makita T, et al. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children. J Clin Pharm Ther. 2008;33(1):31-38
15. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan realtime PCR. Hum Mutat. 2003;22(6):476-485 (Pubitemid 38009951)
16. Vairavan R. AutoGenomics, Inc. Pharmacogenomics. 2004;5(5):585-588
17. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83(2):234-242
18. Barnhart JW, Caldwell WJ. Gas chromatographic determination of hydrocodone in serum. J Chromatogr. 1977;130:243-249
19. Jenkins AJ, Lavins ES, Hunek C. Prevalence of dihydrocodeine in hydrocodone positive postmortem specimens. J Forensic Leg Med. 2009;16(2):64-66
20. Morrow PL, Faris EC. Death associated with inadvertent hydrocodone overdose in a child with a respiratory tract infection. Am J Forensic Med Pathol. 1987;8(1):60-63
21. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos. 1997;25(5):623-630 (Pubitemid 27213105)
22. Horton R, Barber C. Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD. J Pain Symptom Manage. 2009;37(6):e2-e5
23. Redington K, Wells C, Petito F. Erythromycin and valproate interaction. Ann Intern Med. 1992;116:877-878
24. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32(5):554-563
25. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003;37(suppl 2):25-42
26. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism [published correction appears in N Engl J Med. 2005;352(6):638]. N Engl J Med. 2004;351(27):2827-2831
27. US Food and Drug Administration. FDA public health advisory: important information for the safe use of tussionex pennkinetic extended-release suspension. Available at: www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ ucm049680.htm. Accessed July 16, 2009